Inotuzumab ozogamicin

{
  "id": "MLC-T-ONC-004338",
  "term": "Inotuzumab ozogamicin",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults and children aged 1 year and older with B-cell acute lymphoblastic leukemia that is CD22 positive (expresses the protein CD22). It is used in patients whose cancer came back or did not get better with other treatment. It is also being studied in the treatment of other types of cancer. Inotuzumab ozogamicin contains a monoclonal antibody that binds to CD22, which is found on some leukemia cells. It also contains an anticancer drug, which may help kill cancer cells. Inotuzumab ozogamicin is a type of antibody-drug conjugate. Also called Besponsa.",
    "A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora."
  ],
  "synonyms": [
    "Besponsa"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/inotuzumab-ozogamicin/"
}